When NeuroMetrix first unveiled the Quell a few years ago, its promise was a drug-free alternative using the body’s own mechanisms to combat chronic pain. Version 2.0 carries on with the same goal; ...
WOBURN, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NURO) today announced that it has launched a marketing initiative focusing on chronic knee pain. This effort includes ...
ROCKAWAY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (“ECOR,” “electroCore,” or the “Company”) (Nasdaq: ECOR), a commercial-stage ...
New design and features of Quell 2.0 NeuroMetrix focused largely on two things to differentiate version 2.0: make the device smaller, and more functional with the mobile app for iOS and Android. The ...
About one-quarter of U.S. adults suffer from frequent knee pain, which limits function, decreases mobility, impacts sleep and reduces quality of life. Chronic knee pain is typically treated with oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results